Print Page  |  Close Window

Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by market... Read more

Stock Quote

PTGX (Common Stock)
$12.31 + 0.40 (3.36%)
Exchange :NASDAQ
Volume :23,904
Today's Open$11.99
Previous Close$11.91
Data as of August 21, 2017 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $12.31 with a 52 week high of $26.36 and a 52 week low of $8.00.

Recent Press Releases

August 08, 2017

Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights read more

June 08, 2017

Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors read more

May 30, 2017

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease read more

Upcoming Events

There are currently no events scheduled.


Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.